Acumen Pharmaceuticals, Inc. (ABOS)
NasdaqGS: ABOS
· 即時價格 · USD
3.09
-0.01 (-0.32%)
收盤價： Sep 03, 2026, 3:59 PM
股價、關鍵數字和最新消息，都在這一頁。
Acumen Pharmaceuticals, Inc.（ABOS）股價、分析與資料
-0.32% (1D)
| 買價 | 2.08 |
| 市值 | 223M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -105M |
| 0.38 | |
| -1.63 | |
| n/a | |
| -2.16 | |
| P/B (ttm) | 3.90 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 11, 2026 |
| 賣價 | 3.81 |
| 成交量 | 452,340 |
| 20 日平均成交量 | 468,092 |
| 開盤價 | 3.13 |
| 前收盤價 | 3.10 |
| 當日區間 | 3.05 - 3.16 |
| 52 週範圍 | 1.21 - 3.60 |
| 分析師 | n/a |
| 目標價 | 8 (158.9%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcu...
完整的公司簡介財報驚奇
Acumen Pharmaceuticals 已於 Aug 12, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.45 低於預期 -0.04, 年增 33.82% 成長.
第 1 頁，共 2 頁